Supplementary Protection Certificate (SPC) Summary | |||
SPC No. | 2017/044 | ||
---|---|---|---|
Date of filing | 26/10/2017 | ||
Notification of Application Published | 29/11/2017 | ||
Status | Rejected | ||
Notification of Grant Published | |||
Date of Expiry of SPC | |||
Applicant |
ROCHE GLYCART AG Wagistrasse 18 8952 Schlieren-Zuerich SWITZERLAND |
||
Patent Number | 2464382 | ||
Title of Invention | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE | ||
Date of Expiry of Patent | 11/08/2030 | ||
Product Type | Medicinal Product | ||
Product Identity | Obinutuzumab in combination with Bendamustine | ||
Market Authorisation | Ireland | ||
Authorisation No | EU/1/14/937 | ||
Authorisation Date | 13/06/2016 | ||
Identity of Product Authorised | Gazyvaro-Obinutuzumab in combination with Bendamustine | ||
Address for Service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||
Renewal Fees | |||
31/10/2017 | Request for grant a Supplementary Protection Certificate filed on 26/10/2017, numbered 2017/044. | ||
08/12/2020 | Request for grant of Supplementary Protection Certification No. 2017/044 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||
24/03/2021 | Written grounds of decision issued on 19 January 2021. |